|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:can_lead_to
|
EDIT-101
EDIT-301
|
|
gptkbp:ceo
|
Cynthia Collins
|
|
gptkbp:clinical_trial
|
gptkb:sickle_cell_disease
gptkb:public_company
gptkb:sunglasses
safety and efficacy
gene therapies
|
|
gptkbp:collaborations
|
gptkb:Harvard_University
gptkb:Massachusetts_Institute_of_Technology
academic institutions
|
|
gptkbp:community_engagement
|
patient advocacy
|
|
gptkbp:employees
|
over 100
|
|
gptkbp:focus
|
gene editing
|
|
gptkbp:focus_area
|
oncology
hematology
ophthalmology
|
|
gptkbp:founded
|
gptkb:2013
|
|
gptkbp:founder
|
gptkb:George_Daley
gptkb:Jennifer_Doudna
gptkb:J._Keith_Joung
|
|
gptkbp:funding
|
grants
investments
private investments
public offerings
|
|
gptkbp:future_goals
|
enhance technology
expand pipeline
increase collaborations
|
|
gptkbp:has_advisory_board
|
experts in gene editing
|
|
gptkbp:headquarters
|
gptkb:Cambridge,_Massachusetts
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Editas Medicine
|
|
gptkbp:instruction_set
|
therapeutics
|
|
gptkbp:invention
|
gene editing technologies
|
|
gptkbp:investment
|
Venture capital
|
|
gptkbp:investment_focus
|
rare diseases
common diseases
|
|
gptkbp:leadership
|
experienced executives
|
|
gptkbp:mission
|
transform medicine through gene editing
|
|
gptkbp:partnerships
|
gptkb:Bristol-Myers_Squibb
gptkb:Allergan
biopharmaceutical companies
|
|
gptkbp:publications
|
peer-reviewed journals
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
clinical trials
|
|
gptkbp:research
|
gptkb:CRISPR_technology
|
|
gptkbp:research_focus
|
genetic disorders
|
|
gptkbp:stock_exchange
|
gptkb:NASDAQ
|
|
gptkbp:stock_symbol
|
EDIT
|
|
gptkbp:technology
|
gptkb:CRISPR
|
|
gptkbp:vision
|
cure genetic diseases
|
|
gptkbp:website
|
editasmedicine.com
|
|
gptkbp:bfsParent
|
gptkb:Synthego
gptkb:SGMO
|
|
gptkbp:bfsLayer
|
5
|